North China Pharmaceutical Company Ltd.SSE: 600812

Report for Q3 2025

Oct 25, 2025 · Issued by North China Pharmaceutical Company Ltd. via Shanghai Stock Exchange

Filed with SSE · Oct 25, 2025

On 6ix: 6ix.com/news/report-for-q3-2025-203

Report for Q3 2025

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

6ix hasn’t read this filing yet.

North China Pharmaceutical Company Ltd. on 6ix

Earlier from North China Pharmaceutical

Announcement on the Results of Issuance of the 2025 Phase I Science and Technology Innovation BondsOct 24, 2025
Indicative Announcement on Postponing Election of Board of Directors at Expiry of Term of OfficeOct 11, 2025
Announcement on Attending 2025 Online Collective Reception Day for Investors of Listed Companies in Hebei Jurisdiction and 2025 Semi-annual Report Collective Performance BriefingSep 11, 2025
2025 Semi-annual ReportAug 14, 2025
Announcement on Implementation of Dividend Distribution for 2024Jul 19, 2025

Later from North China Pharmaceutical

Announcement on Obtaining the Notice of Approval for Marketing Application of Chemical APIs by SubsidiaryNov 5, 2025
Announcement on Cashing Completion of Phase I Short-term Financing Bonds of 2025Nov 18, 2025
Announcement on Convening the Q3 2025 Performance BriefingNov 20, 2025
Announcement on Resolutions of the 24th Meeting of the 11th Board of DirectorsNov 29, 2025
Announcement on Resolutions of the 25th Meeting of the 11th Board of DirectorsDec 16, 2025

All North China Pharmaceutical news releases

Follow North China Pharmaceutical into a list and get an email when it puts out news.

Follow North China Pharmaceutical